Acute OXM infusion improves glucose tolerance in T2DM patients making dual agonists of the glucagon receptors and GLP-1R new promising treatments for diabetes and obesity with the potential for weight loss and glucose lowering superior to that of GLP-1R agonists (81, 82). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.